Basilea recorded another strong year in FY24, its third successive year of cash flow positivity and its strongest operating performance to date. Lead drug Cresemba continued to dominate performance on broad-based demand, contributing 85-90% of FY24 revenue of CHF208.5m, spearheading the guidance be
